Breast cancer: Evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging

Radiology

Volumn 261, Issue 3, 2011, Pages 735-743

  Chen, Jeon Hor ^a,b,c,d   Bahri, Shadfar ^a,b   Mehta, Rita S ^b   Kuzucan, Aida ^a   Yu, Hon J ^a,b   Carpenter, Philip M ^a   Feig, Stephen A ^b   Lin, Muqing ^a   Hsiang, David J B ^b   Lane, Karen T ^b   Butler, John A ^b   Nalcioglu, Orhan ^a,b   Su, Min Ying ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GADODIAMIDE; HORMONE RECEPTOR; KI 67 ANTIGEN; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG RESPONSE; FALSE NEGATIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 81555205695     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11110814     Document Type: Article

References (36)

1. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007;94(10):1189-1200. (Pubitemid 47584766)
2. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18(12):1927-1934. (Pubitemid 350286227)
3. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26(5):778-785. (Pubitemid 351264391)
4. Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008;26(2):246-252.
5. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25(28):4414-4422. (Pubitemid 350013847)
6. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 2002;72(2):145-152. (Pubitemid 34407209)
7. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003;181(5):1275-1282. (Pubitemid 37296403)
8. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004;14(8):1371-1379. (Pubitemid 39162217)
9. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005;184(3):868-877. (Pubitemid 43899515)
10. Wasser K, Klein SK, Junkermann H, et al. Neoadjuvant chemotherapy of breast carcinomas: what post-therapeutic (preoperative) information is provided by quantitative dynamic MRI? [in German]. Radiologe 2007;47(5):421-429. (Pubitemid 46902828)
11. Bhattacharyya M, Ryan D, Carpenter R, Vinnicombe S, Gallagher CJ. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2008;98(2):289-293. (Pubitemid 351161258)
12. Akazawa K, Tamaki Y, Taguchi T, et al. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 2006;12(2):130-137.
13. Bahri S, Chen JH, Mehta RS, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 2009;16(6):1619-1628.
14. Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008;112(1):17-26.
15. Rakow-Penner R, Daniel B, Yu H, Sawyer-Glover A, Glover GH. Relaxation times of breast tissue at 1.5T and 3T measured using IDEAL. J Magn Reson Imaging 2006;23(1):87-91. (Pubitemid 43100723)
16. Kuhl CK, Jost P, Morakkabati N, Zivanovic O, Schild HH, Gieseke J. Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology 2006;239(3):666-676. (Pubitemid 43830601)
17. Norris DG. High field human imaging. J Magn Reson Imaging 2003;18(5):519-529. (Pubitemid 37339796)
18. Morakkabati-Spitz N, Gieseke J, Kuhl C, et al. MRI of the pelvis at 3 T: very high spatial resolution with sensitivity encoding and flip-angle sweep technique in clinically acceptable scan time. Eur Radiol 2006;16(3):634-641. (Pubitemid 44149375)
19. Kuhl CK, Kooijman H, Gieseke J, Schild HH. Effect of B1 inhomogeneity on breast MR imaging at 3.0 T. Radiology 2007;244(3):929-930. (Pubitemid 47292110)
20. Mann RM, Kuhl CK, Kinkel K, Boetes C. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol 2008;18(7):1307-1318.
21. Azlan CA, Di Giovanni P, Ahearn TS, Semple SI, Gilbert FJ, Redpath TW. B1 transmissionfield inhomogeneity and enhancement ratio errors in dynamic contrast-enhanced MRI (DCE-MRI) of the breast at 3T. J Magn Reson Imaging 2010;31(1):234-239.
22. Jones RL, Lakhani SR, Ring AE, Ashley S, Walsh G, Smith IE. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 2006;94(3):358-362. (Pubitemid 43237560)
23. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19(22):4224-4237. (Pubitemid 33081640)
24. Loibl S, von Minckwitz G, Raab G, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol 2006;13(11):1434-1442. (Pubitemid 44749654)
25. Aziz D, Rawlinson E, Narod SA, et al. The role of reexcision for positive margins in optimizing local disease control after breastconserving surgery for cancer. Breast J 2006;12(4):331-337. (Pubitemid 43989977)
26. Haacke EM, Brown RW, Thompson MR, et al. Magnetic resonance imaging: physical principles and sequence design. New York, NY : Wiley, 1999;1-914.
27. Bottomley PA, Foster TH, Argersinger RE, Pfeifer LM. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med Phys 1984;11(4):425-448. (Pubitemid 14057394)
28. Jezzard P, Duewell S, Balaban RS. MR relaxation times in human brain: measurement at 4 T. Radiology 1996;199(3):773-779. (Pubitemid 26157483)
29. Crooks LE, Arakawa M, Hoenninger J, McCarten B, Watts J, Kaufman L. Magnetic resonance imaging: effects of magnetic field strength. Radiology 1984;151(1):127-133. (Pubitemid 14170010)
30. Wasser K, Sinn HP, Fink C, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 2003;13(6):1213-1223. (Pubitemid 36790621)
31. Honkoop AH, Pinedo HM, De Jong JS, et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997;107(2):211-218. (Pubitemid 27098173)
32. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002;95(4):681-695. (Pubitemid 34845919)
33. Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg 2008;95(4):433-437.
34. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003;98(6):1150-1160. (Pubitemid 37099899)
35. Tse GM, Chaiwun B, Wong KT, et al. Magnetic resonance imaging of breast lesions: a pathologic correlation. Breast Cancer Res Treat 2007;103(1):1-10. (Pubitemid 46653267)
36. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11(16):5678-5685. (Pubitemid 41170290)